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Pro®laggrin is expressed in the differentiating granu-
lar layer of epidermis and other strati®ed epithelia,
where it forms a major component of cytoplasmic
keratohyalin granules. It consists of two distinct
domains, an N-terminal S100-like Ca2+- binding
domain containing two EF-hands and multiple ®lag-
grin units that aggregate keratin ®laments in the stra-
tum corneum. Here, we report structure±function
studies of the N-terminal peptide from mouse,
human, and rat pro®laggrin. The pro®laggrin N-
terminal peptides of all species contain two S100-like
EF-hands, bipartite nuclear localization sequences,
and proprotein convertase cleavage sites. The nuclear
localization signals in human and mouse pro®laggrin
were shown to be functional by transfection of
epithelial cells and depended on the absence of ®lag-
grin sequences. The nuclear localization of the pro-
cessed (free) N-terminal peptide of human
pro®laggrin is consistent with immunolocalization
®ndings in normal human skin and in parakeratotic
skin disorders, which exhibit nuclear staining of
granular and/or corni®ed layers. The mouse pro-
®laggrin N-terminus undergoes proteolytic process-
ing in two steps, ®rst releasing an N-terminal
peptide containing some ®laggrin sequence and
®nally the free N-terminus of 28±30 kDa; these pep-
tides have cytoplasmic and nuclear distributions,
respectively, when expressed in transfected cells. The
N-terminal processing may occur prior to or simul-
taneously with the proteolytic processing of the
poly®laggrin domain. The nuclear accumulation of
the pro®laggrin N-terminal peptide in epidermis and
in transfected cells strongly suggests a calcium-
dependent nuclear function for the pro®laggrin
N-terminus during epidermal terminal differentia-
tion when the free N-terminus is released from pro-
®laggrin by speci®c proteolysis. Key words: epidermal
differentiation/keratinocyte/nuclear localization/pro®lag-
grin/proteolytic processing/transfection. J Invest Dermatol
119:661±669, 2002
T
he terminal differentiation of epidermal keratinocytes
results in the formation of a mechanically resistant and
toughened structure, the stratum corneum, which
functions to protect mammals against dessication, and
physical and chemical damage. Among the many
morphologic changes that occur in normal epidermis during the
transition from granular to corni®ed cells are the dissolution of the
nucleus and other organelles, the aggregation of the keratin
intermediate ®lament (IF) network into macro®brils, and the
formation of a corni®ed cell envelope consisting of loricrin, the
small proline-rich proteins, involucrin, and other proteins that are
crosslinked by transglutaminases in the stratum corneum (Nemes
and Steinert, 1999; Presland and Dale, 2000). Although the
mechanism of nuclear destruction is not understood, the cross-
linking and collapse of keratin IFs into macro®bril bundles is
mediated by the IF-associated protein ®laggrin, an abundant
protein present in granular and transition cells produced by the
speci®c proteolysis of pro®laggrin.
Pro®laggrin is a large, highly phosphorylated, insoluble protein
consisting of multiple (10±12 in human, 20 or more in rodents)
®laggrin units joined by linker peptides. Pro®laggrin is expressed in
the granular layer where it is localized within electron-dense
nonmembrane bound keratohyalin granules (reviewed in Dale et al,
1994; Presland and Dale, 2000). This sequestration into kerato-
hyalin is believed to protect the epithelial cell from the deleterious
effects of premature keratin aggregation by ®laggrin (Dale et al,
1997; Kuechle et al, 1999; Presland et al, 2001).
The pro®laggrin N-terminus consists of two distinct domains: a
conserved A domain that contains two Ca2+- binding S100-like
EF-hands that each bind a Ca2+ ion, and a less conserved cationic B
domain (Presland et al, 1992, 1995; Markova et al, 1993).
Pro®laggrin belongs to a growing family of high molecular weight
proteins with N-terminal S100 domains fused to structurally
distinct repetitive regions that are proposed to function as IF-
associated proteins and/or corni®ed envelope components (Fietz et
al, 1993; Lee et al, 1993; Krieg et al, 1997; Makino et al, 2001). The
genes encoding these ``fused S100'' proteins are among a large
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number of epidermally expressed genes that map to human
chromosome 1q21 in an »1.5 mB region termed the epidermal
differentiation complex (EDC) (Marenholz et al, 1996; Mischke et
al, 1996; South et al, 1999). An equivalent EDC is present on
mouse chromosome 3 (Song et al, 1999).
During terminal differentiation pro®laggrin is processed by
several endoproteases to generate two major products: ®laggrin and
the N-terminal peptide. Pro®laggrin processing to ®laggrin requires
both the removal of multiple phosphates from each ®laggrin unit
within pro®laggrin by phosphatases and its speci®c proteolysis by a
number of proteases (Lonsdale-Eccles et al, 1982; Harding and
Scott, 1983; Resing et al, 1989; Kam et al, 1993). The proteases that
are involved in pro®laggrin processing include pro®laggrin
endoproteinase 1 (PEP1), a chymotrypsin-like protease (Resing et
al, 1995b), calpain (Resing et al, 1993a; Yamazaki et al, 1997), and
furin, a member of the proprotein convertase (PC) family of
endoproteases (Pearton et al, 2001). The order of these processing
events has not been elucidated; however, as pro®laggrin inter-
mediates containing two or more ®laggrin units lack detectable
phosphate it is thought that most dephosphorylation occurs before
processing of the poly®laggrin domain occurs (Harding and Scott,
1983).
Filaggrin binds to cytoplasmic keratin IFs to form the
macro®brils that are retained in corni®ed cells, whereas the N-
terminal peptide localizes to nuclei of epidermal granular and
transition cells (Ishida-Yamamoto et al, 1998; Presland and Dale,
2000). The mechanism and function of this nuclear translocation is
unclear. In loricrin keratoderma, a disease affecting palm and sole
skin characterized by parakeratosis in the lower corni®ed layers, the
pro®laggrin N-terminus is associated with nuclear aggregates of a
mutant loricrin protein that might prevent it from functioning
normally (Ishida-Yamamoto and Iizuka, 1998; Ishida-Yamamoto et
al, 1998). Studies of affected patients and transgenic mice that are
either loricrin-de®cient and/or express the same mutant protein
have shown that the loricrin mutation is pathogenic, and that the
resulting skin disease is probably due to disruption of nuclear events
during terminal differentiation rather than to an absence of loricrin
from corni®ed envelopes (Ishida-Yamamoto et al, 2000; Koch et al,
2000; Suga et al, 2000).
In this paper, we report the sequence of the mouse and rat
pro®laggrin N-termini and show its similarity to the human
pro®laggrin N-terminus in terms of both structure and proteolytic
processing in keratinocytes. Like its human counterpart, the mouse
N-terminal peptide is speci®cally cleaved in vivo during terminal
differentiation. We show that the cationic B domain of the
pro®laggrin N-terminus contains functional bipartite nuclear
localization sequence(s) (bNLSs) that facilitate nuclear accumula-
tion in keratinocytes. Removal of ®laggrin sequences by proteolytic
cleavage, however, is required for this nuclear translocation.
Pro®laggrin processing therefore provides a potential link between
two major events of terminal differentiation: the aggregation of
keratin ®laments and nuclear dissolution.
MATERIALS AND METHODS
Isolation and characterization of mouse and rat pro®laggrin
genomic and cDNA clones A 129/SvJ mouse genomic BAC library
(Genome Systems, St. Louis, MO) was screened with a pair of
polymerase chain reaction (PCR) primers speci®c for the mouse
pro®laggrin 3¢ noncoding sequence. BAC plasmid DNA was isolated
from overnight cultures of each clone using Nucleobond AX columns
(The Nest Group, Southboro, MA). The pro®laggrin gene was localized
within BAC clones by southern blot hybridization of restriction digests
with coding and 3¢ noncoding ®laggrin DNA probes labeled with
[a-32P]-dCTP (3000 Ci per mmol) (Sambrook et al, 1989). Several
restriction endonuclease fragments that hybridized with coding probes
were subcloned into pGEM5Zf+ and pGEM7Zf+ vectors (Promega,
Madison, WI) and sequenced to derive the 5¢ end of the mouse
pro®laggrin coding sequence. To con®rm the coding sequence and
exon/intron organization of the mouse pro®laggrin gene, the cDNA
sequence was isolated by reverse transcription PCR (RT-PCR) of
mouse epidermal RNA as described previously (Presland et al, 2000)
using the following primers derived from the genomic sequence: 5¢-
GTGCATACACACTACTA (upstream exon 2 primer) and 5¢-
AGAAAGTAGTAGGCATG (downstream exon 3 primer). The cDNA
product (»1 kb) containing the N-terminal domain of mouse pro®laggrin
was cloned into TOPO-TA vector (Invitrogen, Carlsbad, CA) for
sequence analysis.
For rat pro®laggrin, genomic and cDNA sequences were obtained by
PCR ampli®cation of DNA and RNA isolated from rat epidermal
keratinocytes (REKs) (Baden and Kubilus, 1983; Haydock et al, 1993).
Genomic DNA was isolated using a Qiamp tissue kit (Qiagen,
Chatsworth, CA). For genomic DNA ampli®cations, PCR assays (32
cycles at 94°C for 50 s, 47.5°C for 60 s, and 72°C for 90 s) were
performed using Taq polymerase (Promega, Madison, WI) in the
presence of 5% dimethylsulfoxide and 2.5 mM MgCl2. The 5¢ primer
corresponded to nucleotides 1±24 of the coding region of the human
pro®laggrin sequence (5¢-ATGTCTACTCTCCTGGAAAACATC-3¢;
GenBank accession L01088). The 3¢ primer was directed against the
linker region of the rat ®laggrin sequence (5¢-GGACTC-
GTCCTCGGTTTCTTCTACACC-3¢; GenBank accession M21759).
The resulting 2.2 kb PCR products were cloned into pCR2.1 TA
(Invitrogen) for sequencing. Sequence analysis of both mouse and rat
pro®laggrin clones was performed by dye terminator cycle sequencing
using the BigDye kit (Perkin Elmer ABI, Foster City, CA). To obtain
the entire sequence for both strands of mouse and rat pro®laggrin,
internal primers were synthesized and the resultant overlapping sequences
were assembled using either the Sequencher program (Gene Codes, Ann
Arbor, MI) or PC/GENE.
To determine the exon/intron boundaries of the rat pro®laggrin
sequence, total RNA was extracted from con¯uent REKs and single
stranded cDNA was prepared as described previously (Presland et al,
2001). PCR was performed with the primers 5¢-CACTAG-
CATGATTGA CATATTCC-3¢ and 5¢-TTGAAGTCTGCCCTT-
GCCCG-3¢, using 32 cycles of 94°C for 50 s, 53°C for 45 s, and 72°C
for 50 s in the presence of Taq polymerase (Promega) and Taq extender
(Stratagene, La Jolla, CA). The PCR product (1078 bp) was cloned into
pCR2.1 (Invitrogen) and sequenced. A partial genomic sequence was
also obtained from Sprague-Dawley rats that express a small 350 kDa
variant of pro®laggrin containing 7±9 ®laggrin units (K. Resing, personal
communication) using the 5¢ primer CATGCAAATGCTAGATGTGG-
3¢ and the same 3¢ primer used above.
The N-terminal sequence of rat pro®laggrin protein was veri®ed by
Endolys C digestion of puri®ed rat pro®laggrin followed by matrix
assisted laser desorption ionization mass spectrometry and electrospray
ionization mass spectrometry (Resing et al, 1993b; 1995a) to be
STLLESITSMIDIFQQYSNNDK (K. Resing, personal communication).
This sequence exhibits four amino acid differences from mouse and nine
from human pro®laggrin (see Fig 1B).
Sequence alignments were performed using the programs NALIGN
(PC/GENE) and CLUSTALW (PBIL) and outputted with
BOXSHADE. Peptide motifs were identi®ed using the programs
PROSITE (http://c.expasy.org/prosite) and PSORT II (http://psort.-
nibb.ac.jp).
Production of an antibody against the mouse pro®laggrin N-
terminus A polyclonal antipeptide antibody, Am1, was developed
against a 15 amino acid sequence (E38GQLQAVLKNPDDQD53) in the
region between the EF-hands of the mouse A domain (see Fig 1B)
(Genemed Synthesis, San Francisco, CA). This sequence is equivalent to
the peptide used to prepare the human-A-domain-speci®c antibody
(Presland et al, 1997). The antibodies were af®nity puri®ed prior to use.
Immunoblotting of mouse and human extracts Cell or tissue
extracts were prepared in urea±Tris buffer as previously described
(Presland et al, 1997), or in a modi®ed RIPA buffer containing 1%
Nonidet P-40 (Pearton et al, 2001). For immunoblotting, equal protein
loadings were resolved on either 7%±12% or 10%±15% gradient sodium
dodecyl sulfate (SDS) polyacrylamide gels and electroblotted onto
nitrocellulose membranes (Schleicher & Schuell, Keene, NH). After
blocking with 2% nonfat dry milk powder the membranes were probed
with primary antibody and detected with a horseradish-peroxidase-
conjugated donkey antirabbit IgG (Amersham, Arlington Heights, IL)
using the Renaissance chemiluminescent substrate (NEN, Boston, MA).
Mouse keratinocyte culture Mouse epidermal keratinocytes (MEKs)
were cultured in low (0.06 mM) Ca2+ NIH-3T3 ®broblast conditioned
medium as described previously (Hager et al, 1999). Cells were passaged
and seeded at low density (2.4 3 104 cells per cm2) and reached
con¯uence in 7 d. Con¯uent cultures were fed with 3T3-conditioned
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medium every 48 h and the detached cells were harvested by
centrifugation of the culture medium. The cell pellet was washed with
cold Dulbecco's phosphate-buffered saline (PBS) before extraction.
Adherent cells were washed twice with cold PBS before being scraped
from the dish and extracted in urea±Tris or modi®ed RIPA buffer.
Unextracted cell pellets and cell extracts were stored at ±80°C until use.
Protein concentration was determined using the Bio-Rad protein assay
(Bio-Rad, Hercules, CA) and equal protein loads from each pellet were
loaded onto SDS polyacrylamide gels and blotted onto nitrocellulose for
Western blot detection.
The phosphorylation state of pro®laggrin and its processing products
was determined by labeling con¯uent keratinocytes with radiolabeled
phosphate. Two day postcon¯uent MEKs were grown in the presence of
100 mCi [32P]-orthophosphate for 24 h. Labeled cells were harvested by
centrifugation of the medium (for detached cells) or scraping the dish
surface (for attached cells). After washing away unbound orthophosphate
in cold PBS, cells were extracted in urea±Tris or RIPA buffer. The
RIPA buffer extract was subjected to immunoprecipitation using either
antimouse pro®laggrin antibody (Covance, Richmond, CA) or the Am1
antibody. Antibody±antigen complexes were recovered using protein-A-
coated paramagnetic beads (Dynal, Lake Pleasant, NY), eluted with 0.1
M glycine pH 2.8 or by heating at 45°C for 15 min in 2% SDS
Laemmli loading buffer. The extracts and immunoprecipitates were run
on 7.5%±12% SDS polyacrylamide gels and either blotted onto
nitrocellulose for Western analysis or dried and exposed to X-ray ®lm.
Immuno¯uorescence microscopy Immuno¯uorescence was per-
formed on frozen or methyl Carnoys ®xed tissue samples embedded in
paraf®n (Presland et al, 1997) or transfected cells grown on glass
coverslips ®xed with ice-cold methanol:acetone (3:1) (Dale et al, 1997).
After rehydration (for Carnoys ®xed tissues) sections were washed in
Tris-buffered saline (TBS) and processed for single or double
immuno¯uorescence. Sections were incubated with primary antibody
overnight at 4°C in TBS containing 1% bovine serum albumin. The
primary antibodies were detected using either ¯uorescein isothiocyanate
(FITC)-labeled goat antirabbit IgG (Vector Laboratories, Burlingame,
CA) or biotinylated goat antirabbit IgG followed by streptavidin
conjugated to Texas Red (Vector Laboratories). For detection of mouse
®laggrin a directly labeled FITC-anti®laggrin rabbit IgG (Covance) was
used after the initial secondary was removed. Multiple rinses in TBS
were done between each step. For DNA staining, samples were
incubated in 0.001% 4¢,6-diamidino-2-phenylindole dihydrochloride
(DAPI) (Sigma, St. Louis, MO) for 10 min and then washed with water.
Samples were air-dried and coverslipped using Prolong mounting
medium (Molecular Probes, Eugene, OR) to minimize fading. All the
samples were observed under an epi¯uorescence Nikon-SA Microphot
microscope and digital images were collected using a CCD camera
(Photometrics, Tucson, AZ).
Constructs and transfection procedures DNA constructs were
prepared from mouse and human pro®laggrin cDNA clones (Presland et
al, 1997; this paper) by a PCR approach followed by cloning into NT-
GFP-TOPO (Invitrogen) to generate constructs with an N-terminal
green ¯uorescent protein (GFP) tag. The primers used for cloning the
complete mouse pro®laggrin N-terminus were 5¢-TCCGCTCTC-
CTGGAAAGCATC-3¢ (MP-5) and 5¢-TTAGCCTGCCCTGGATCT-
CCTCTG-3¢ (MP-3); the human primers were 5¢-TCTACTCTC-
CTGGAAAACATCTTTG-3¢ (HP-5) and 5¢-TTACCTACGCTTTCT-
B
                             **************
Human    1 MSTLLENIFAIINLFKQYSKKDKNTDTLSKKELKELLEKEFRQILKNPDDPDMVDVFMDH
Mouse    1 MSALLESITSMIEIFQQYSTSDKEEETLSKEELKELLEGQLQAVLKNPDDQDIAEVFMQM
Rat      1 MSTLLESITSMIDIFQQYSNNDKEEETLSKEELKELLEGELQAVLKNPNDQDIAEVFMQM
            ************
Human   61 LDIDHNKKIDFTEFLLMVFKLAQAYYESTRKENLPISGHKHRKHSHHDKHEDNKQEENKE
Mouse   61 LDVDHDDKLDFAEYLLLVLKLAKAYYEASKNESFQTHGSNGRSKTDYKGLEEEGEEGNEQ
Rat     61 LDVDHDDKIDFTEYLLMVLKLAQAYYETSKKRRSQTKESGKRNEHDYKGHEERREK-VQR
                             E
Human  121 NRKRPSSLERRNNRKGNKGRSKSPRETGGKRHESSSEKKERKGYSPTHREEEYGKNHHNS
Mouse  121 NLRRRH---GGTDGKRKSDRTRSPNGKRGKRQESRCRSEGKDKHRR---EPEKHRHQQDS
Rat    120 rhrrrN---SGTDGKQENERSKSPRGRGKKRRGSSTISEESDTIRNS--DTENKRHHHGS
                                       N       N
Human  181 SKKEKNKTENTRLGDNRKRLSERLEEKEDNEEGVYDYENTGRMTQKWIQSGHIATYYTIQ
Mouse  175 KRKQRHGSGSTERKDNRN--KKNRQSKERNYDEIYDNG---KYNEDWEAS-YNNCYYKTQ
Rat    175 NrrqrrGSNSSDRKETRS--KKHREVKETN-AGIYNDG---KDGQDWEVN-YENCYYKTE
                                       R   E
Human  241 DEAYDTTDSLLEENKIYERSRSSDGK-------SSSQVNRSRHENTSQVPLQESrtrkrr
Mouse  229 NTTLDQREG---NRRPRADSQKEPQSFHGQADNSDSEGGRQ--QSHSKPSPVradqrrsr
Rat
A   B              Truncated FG   Filaggrin unit 1
Ca2+ Ca2+ NLS (4)
PC/furin site
C
human NLS  122 RKRpsslerrnnRKgnK  138
mouse NLS1 132 KRKsdrtrspngKRgKR  148
mouse NLS2 147 KRqesrcrsegkdKHRR  163
mouse NLS3 162 RRepekhrhqqdsKRKq  178
mouse NLS4 175 KRKqrhgsgsteRKdnR  191
rat NLS1   101 KRnehdykgheeRReKvq 118
rat NLS2   179 RRgsnnsdrketrsKKhR 196
228 ESNRELREG---QNHKTK
         Q      R
A
t
n
Figure 1. Structure of mouse pro®laggrin
and conservation of functional elements
among human and rodent pro®laggrins. (A)
Structure of mouse pro®laggrin. Mouse
pro®laggrin consists of an N-terminal A and B
domain (283 amino acids) followed by a truncated
®laggrin unit of 173 residues and »20 ®laggrin
units. Only the ®rst ®laggrin unit of 250 amino
acids is shown. Like other mammalian
pro®laggrins, the C-terminal end of the protein
contains a truncated ®laggrin unit and unique
peptide of 23 amino acids (Rothnagel et al, 1987;
GenBank Accession Number J03458). The protein
motifs located in the mouse A and B domains are
indicated. (B) Predicted amino acid sequences of
human, mouse, and rat pro®laggrin N-termini.
The S100Ca2+-binding domain is highly conserved
(amino acids 1±80) whereas the B domain is less
conserved. Indicated are the two S100EF-hands
(stars) and the furin/PC cleavage sites (lower case
letters). In human and mouse pro®laggrin, the
single PC cleavage site is located at the end of the
N-terminal sequence, whereas in rat pro®laggrin
they are at amino acids 120±124 and 176±180. The
sequence used to generate the Am1 antibody
speci®c for mouse pro®laggrin (amino acids 38±53)
is underlined. The arrowhead at amino acid 47
indicates the conserved location of the intron
between the two S100-like EF-hands; this intron is
1670 bp and 681 bp in the mouse and rat
pro®laggrin genes, respectively. The solid box
indicates the end of the A domain at residue 80.
Boxed regions indicate amino acid identity
between sequences and light shading indicates
similarity. Residues shown below the rat sequence
indicate amino acid differences seen in the
350 kDa pro®laggrin variant partially sequenced
from Sprague-Dawley rats. (C) Amino acid
sequences of the bipartite nuclear localization
signals in human, mouse, and rat pro®laggrin N-
terminus. The basic amino acids in each sequence
are shown capitalized. The pro®laggrin sequences
reported here have been deposited to Genbank
with accession numbers of AF510859 and
AF510860 (mouse pro®laggrin) and AY102923 (rat
pro®laggrin).
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TGTCCTGG-3¢ (HP-3) (termination codons engineered at the 3¢ end
of each construct are underlined). The human pro®laggrin N-terminal
mutant and deletion constructs were prepared using a similar approach
(see Fig 6; primer sequences are available upon request). Deletion
constructs of the mouse pro®laggrin N-terminus fused to GFP were
prepared in a similar manner using the common upstream primer MP-5
in combination with the following downstream primers: MP192±GFP,
5¢-TTAATTTCTGTTGTCCTTTCTTTCG-3¢; MP174±GFP, 5¢-
TTATGAATCTTGTTGGTGTCTGTG-3¢; MP161±GFP, 5¢-TTA-
ATGTTTATCTTTTCCCTCACTTC-3¢; MP145±GFP, TTATCTTT-
TTCCATTTGGGCTTCTCG-3¢; and MP131±GFP, 5¢-TTATCC-
ATCAGTTCCACCATGCCTC-3¢. All downstream primers contain
termination codons at the end of the encoded pro®laggrin peptide
(underlined). All constructs were veri®ed by DNA sequencing.
COS-7 cells were transfected with DNA constructs at 60%±70% of
con¯uence using Lipofectamine reagent (Invitrogen) as described previ-
ously (Dale et al, 1997). Cells were harvested or ®xed for staining 48 or
72 h post-transfection. REKs [a gift of H. Baden, Massachusetts General
Hospital and Cutaneous Biology Research Center, Boston, MA (Baden
and Kubilus, 1983)] were transfected as described previously (Dale et al,
1997). GFP epi¯uorescence and antibody labeling of transfected cells
with N-terminal antibodies were carried out as described previously
(Dale et al, 1997; Kuechle et al, 1999).
RESULTS
Characterization of the mouse and rat pro®laggrin N-
termini and identi®cation of putative functional
motifs Mouse and rat pro®laggrin genomic and cDNA clones
were obtained by a combination of approaches (see Materials and
Methods), and clones were sequenced to derive the corresponding
N-terminal protein sequences. The mouse and rat pro®laggrin N-
terminal peptides are 283 and 242 amino acids in length,
respectively, including the initiator methionine. The A domain
that contains the S100-like EF-hands is highly conserved between
human, mouse, and rat pro®laggrin (56.8% identity, 72.8%
similarity; Fig 1B). Other features shared are PC/furin-like
cleavage sites located at the end of the unique non®laggrin N-
terminal region (human, mouse) or within the B domain (rat), and
the presence of bNLSs in the cationic B domain (Fig 1C) that
conform to the consensus described for this motif (Dingwall and
Laskey, 1986). Overall the N-termini of human, mouse, and rat
pro®laggrin show 28.9% identity and 43.4% similarity. As expected
from evolutionary considerations, the mouse pro®laggrin N-
terminal sequence exhibits a greater similarity to rat than to
human (58.3% vs 38% identity, respectively); this is most readily
apparent in the B domain (Fig 1B). The nucleic acid and predicted
amino acid sequences of the mouse pro®laggrin N-terminus
obtained from 129/SvJ (BAC clone) and C57BL/6J (cDNA
sequence) mice were identical, whereas there were seven amino
acid differences between the two rat pro®laggrin sequences
examined (Fig 1B).
Mouse pro®laggrin undergoes N-terminal processing during
epidermal differentiation A polyclonal antibody, Am1, was
produced against a sequence in the mouse A domain
(E38GQLQAVLKNPDDQD53) (Fig 1B). This sequence has a
high Smith±Waterman antigenicity index and is exposed on the
surface in crystal structures of other S100 proteins such as S100B
and S100A7 (Kilby et al, 1996; Brodersen et al, 1998; Sastry et al,
1998; Smith and Shaw, 1998). On Western blots, the mouse N-
terminal antibody Am1 recognized high molecular weight mouse
pro®laggrin, a 90 kDa band that probably represents an
intermediate in pro®laggrin processing, and a series of smaller
polypeptides consisting of a doublet at 28±30 kDa and a band at
»16 kDa (Fig 2). The 28±30 kDa doublet corresponds closely in
size to the predicted molecular weight of the mouse pro®laggrin N-
terminus (282 residues, 31 kDa) demonstrating that the mouse
pro®laggrin N-terminus undergoes N-terminal processing as has
been described for the human protein (Presland et al, 1997). The
presence of more than one N-terminal peptide may represent
additional proteolytic trimming or phosphorylation.
The Am1 antibody showed a stronger and cleaner reaction in the
presence of 5 mM ethylenediamine tetraacetic acid (data not
shown). This Ca2+ dependence of the Am1 reaction can be
explained by the position of the antigen (residues 38±53) between
the two Ca2+-binding EF-hands in the A domain (Fig 1B). The
binding of Ca2+ to the pro®laggrin A domain apparently abrogates
antibody binding either by steric hindrance or by a conformation
change in the protein, as demonstrated for the human N-terminal
peptide (Presland et al, 1995).
The lower molecular weight peptides of 28±30 kDa and 16 kDa
were present in soluble (nonurea) extracts of mouse skin isolated in
both the presence and absence of detergents (data not shown)
although reaction with peptides of < 20 kDa was variable and
depended on protein load, extraction, and blotting conditions
(compare Figs 2 and 4A). These peptide(s) may represent either
further processing of the mouse pro®laggrin N-terminus or
crossreaction with other S100 proteins (Presland et al, 1997).
The mouse A domain antibody showed no reactivity towards rat
pro®laggrin or processing intermediates, even though the peptide
sequence used to generate the antibody was 87% (13 out of 15
residues) identical with the analogous sequence from rat pro®lag-
grin (Fig 1B).
The mouse pro®laggrin N-terminus localizes to
keratohyalin granules in epidermal granular cells The
Am1 antibody showed strong immunolabeling of keratohyalin
granules in the epidermal granular layer (Fig 3B±D) where it
colocalized with the ®laggrin antibody immunolocalization
(Fig 3A, C). The Am1 staining pattern does not colocalize with
®laggrin in the stratum corneum, however, suggesting a different
fate for this peptide during terminal differentiation.
The pro®laggrin N-terminus undergoes partial processing
in vitro Mouse pro®laggrin undergoes N-terminal processing in
epidermis to release a peptide that corresponds closely in size to the
free mouse N-terminus (Fig 2). To examine pro®laggrin
processing in vitro, MEKs were grown to con¯uence under low
Ca2+ conditions in which the detached cells have been shown
previously to express markers of differentiation such as pro®laggrin
and K1, and to partially process pro®laggrin (Missero et al, 1995; Di
Cunto et al, 1998). MEKs grown under these conditions expressed
pro®laggrin (> 200 kDa) and a protein of 50 kDa that reacted with
both Am1 and ®laggrin antibodies (bar and arrows, respectively,
Fig 4A). The 50 kDa peptide was also detected with ®laggrin
antibody following immunoprecipitation of MEK proteins with the
pro®laggrin Am1 antibody (Fig 4B, arrow). Because the 50 kDa
Figure 2. N-terminal processing of pro®laggrin in mouse
epidermis. A mouse epidermal urea±Tris extract was run on a 7%±12%
SDS polyacrylamide gel, blotted to nitrocellulose membrane, and reacted
with the Am1 antibody directed against the mouse A domain. The
antibody recognizes pro®laggrin and potential large processing products
(bar) as well as bands at »90 kDa, a doublet at 28±30 kDa (arrows), and a
band at 16 kDa (arrowhead).
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peptide reacts with both antibodies it must contain both N-
terminal and ®laggrin sequences, and probably corresponds to an
N-terminal processing intermediate consisting of the N-terminal A
and B domains plus the truncated ®laggrin unit, which is 457 amino
acids in length with a predicted molecular weight of 50.3 kDa. The
28±30 kDa band, corresponding to the fully processed pro®laggrin
N-terminal peptide present in mouse skin, was not detected in
either detached or adherent MEK cells grown in low calcium, or in
cells grown in high calcium to induce differentiation (Fig 4A).
An important aspect of pro®laggrin processing to ®laggrin is the
removal of phosphate by serine/threonine phosphatases, which is
necessary for ®laggrin to associate with keratin ®laments (Harding
and Scott, 1983; Kam et al, 1993). Immunoprecipitation of 32P-
labeled MEK proteins and autoradiography showed that mouse
pro®laggrin was heavily phosphorylated in vitro (as is the case in
epidermis) (Lonsdale-Eccles et al, 1982; Harding and Scott, 1983)
whereas the 50 kDa and 90 kDa N-terminal peptides were not
signi®cantly phosphorylated (Fig 4B). The other 32P-labeled
proteins observed in the 70±30 kDa range might be phosphopro-
teins that associate with the 50 kDa N-terminal peptide.
Filaggrin and pro®laggrin N-terminal sequences specify
cytoplasmic versus nuclear localization in transfected
epithelial cells Previous results demonstrated that the human
N-terminal peptide accumulates in nuclei of granular and transition
cells of normal epidermis and in some parakeratotic skin disorders
where nuclei persist in the stratum corneum (Ishida-Yamamoto et
al, 1998; Presland and Dale, 2000). In contrast, ®laggrin peptide
sequences remain in the cytoplasm associated with keratin
®laments. In order to examine the regulation of nuclear
translocation we utilized transient transfections of multiple
constructs into COS cells and keratinocytes. COS-7 cells
expressing a cDNA construct encoding the N-terminus and the
®rst truncated ®laggrin unit (PFlag467proF; Presland et al, 1997)
exhibited a diffuse and granular cytoplasmic localization (Fig 5A).
In contrast, when ®laggrin sequences were absent from the
expressed proteins, the human and mouse pro®laggrin N-termini
localized almost exclusively to the nuclei of transfected cells as
detected by both GFP epi¯uorescence (Fig 5B±E) and
immunolabeling with N-terminal speci®c antibodies (data not
shown). The nuclear morphology of transfected cells appeared
similar to those of adjacent control cells, suggesting that expression
of N-terminal peptides had no adverse effects on nuclear integrity.
Similar results were obtained when these constructs, i.e., mouse
and human N-terminus containing or lacking ®laggrin sequences,
were transfected into REKs (data not shown).
Identi®cation of functional nuclear localization sequences in
the pro®laggrin N-terminus Both human and mouse
pro®laggrin contain putative bNLSs in the B domain of the N-
terminal peptide (Fig 1B). This sequence usually consists of two
groups of basic residues separated by an »10 residue spacer peptide
of variable sequence (Dingwall and Laskey, 1986). The human
pro®laggrin bNLS identi®ed by the program PSORT II lies
between amino acids 121 and 137 (RKRPSSLERRNNRKGNK,
Fig 1C). To determine the functionality of this bNLS, a series of
constructs was prepared in which this sequence was either mutated
or deleted, and the effect on nuclear accumulation was examined.
As shown in Fig 6, mutation of essential basic residues in the C-
terminal end of this motif (RKGNK to LLGAA) (panels C, D) or
deletion of the entire bNLS (panels E, F) prevented the speci®c
Figure 3. Immuno¯uorescence localization of mouse pro®laggrin
N-terminal and ®laggrin antibodies in newborn skin. Frozen
mouse skin was stained with antibodies against mouse ®laggrin (A) and
the N-terminal (Am1) antibody (B, D). Part (C)is a merged image of (A)
and (B). Both ®laggrin and the Am1 antibody stain keratohyalin granules
in the granular layer (A, B, yellow in C) whereas in the corni®ed and
transition layers the immunostaining no longer colocalizes. The ®laggrin
antibody stains the lower corni®ed layers very strongly but diminishes in
the upper layers due to the degradation of ®laggrin to amino acids. Scale
bars: (A)±(C) 50 mm; (D) 25 mm.
Figure 4. Analysis of pro®laggrin processing in vitro. (A) Detached
MEKs were harvested at 2 d after con¯uence, extracted in urea±Tris
buffer, and run on 7%±12% SDS polyacrylamide gels for Western
blotting. Duplicate blots were probed with antibodies against the mouse
N-terminus (A domain, Am1) and ®laggrin. Detached cells produced
full-length pro®laggrin (bar), as well as a 50 kDa product that reacted
with both the N-terminus and ®laggrin antibodies (arrows). Cultured
MEKs did not fully process pro®laggrin to the 28±30 kDa doublet (left
panel) or mature ®laggrin (Fg, right panel) present in mouse epidermis. (B)
MEK cultures were grown in the presence of 100 mCi of inorganic 32P.
After 24 h the detached cells were harvested and extracted in RIPA
buffer and immunoprecipitated (IP) with the Am1 antibody. The
immunoprecipitated proteins were run on 10%±15% SDS polyacrylamide
gels and either blotted and probed with a ®laggrin antibody (left panel) or
dried down and exposed to X-ray ®lm (right panel). The Am1 antibody
precipitated a 50 kDa protein that reacted with the ®laggrin antibody
(arrow) but no corresponding 32P band was visible in the autoradiograph
(right panel). A number of other non®laggrin or Am1 (data not shown)
reactive bands were labeled with 32P including a high molecular weight
smear (bar) that is probably pro®laggrin. The visualization of pro®laggrin
(> 200 kDa) on the Western blot (left panel) is masked by the very
strong immunoreactive band above 100 kDa, which is the rabbit IgG
reacting with the antirabbit secondary antibody.
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nuclear localization of this peptide in COS-7 cells. These proteins
with bNLS mutations or deletion exhibited a cytoplasmic and
nuclear distribution pattern similar to that of the control GFP
(panels G, H). Removal of sequences C-terminal to the bNLS of
human pro®laggrin, i.e., amino acids 138±293, did not measurably
affect nuclear localization of the N-terminal peptide (compare
Fig 5B, C with Fig 6A, B). Similar results were obtained in REKs
transfected with these same GFP±pro®laggrin N-terminal
constructs (data not shown).
The mouse pro®laggrin N-terminal peptide contains four
potential bNLSs in the B domain (Fig 1C). To assess their
function, deletion constructs were prepared that removed from 0 to
4 of the putative bNLSs. The results show that removal of NLS3
and NLS4 had little effect on nuclear localization of the fusion
protein (Fig 7B); however, removal of NLS2 or all four NLSs
severely abrogated nuclear accumulation in transfected cells
(Fig 7C±E). These results show that NLS1 and NLS2 are essential
for nuclear accumulation of the mouse pro®laggrin N-terminal
peptide, con®rming that these motifs function as nuclear localiza-
tion signals (Table I). The other two NLSs, NLS3 and NLS4,
either are functionally redundant, i.e., are not required for nuclear
targeting of the peptide, or do not function as NLSs.
In summary, these studies demonstrate that both the human and
mouse pro®laggrin N-terminal peptides contain functional bNLSs
Figure 6. Identi®cation of the nuclear
localization sequence in the human
pro®laggrin N-terminus. The indicated GFP
fusion constructs were transfected and analyzed by
epi¯uorescence after either staining with DAPI to
identify nuclei (A, C, E, G) or GFP ¯uorescence
(B, D, F, H). Shown are cells expressing amino
acids 1±137 terminating at the end of the bNLS
(A, B); amino acids 1±137 with the C-terminus of
the bNLS altered from RKGNK to LLGAA (C,
D); and amino acids 1±120 in which the bNLS
was deleted (E, F). Parts (G) and (H) show the
parent GFP protein transfected into cells. Only in
(B) is the pro®laggrin±GFP restricted to the
nucleus; note that mutation or deletion of the
bNLS in human pro®laggrin leads to loss of
preferential nuclear accumulation of transfected
protein. Scale bar: 10 mm.
Figure 5. Cytoplasmic and nuclear
distribution of expressed pro®laggrin N-
terminal peptides. COS-7 cells were transfected
with the indicated constructs and ®xed, and
cellular distribution was examined by staining
either with the human N-terminal B1 antibody
(A) or by GFP auto¯uorescence (B±E). Part (A)
shows that pFLAG467proF protein has a punctate,
mostly cytoplasmic distribution (green, B1
antibody merged with blue DAPI counterstain,
blue) whereas the GFP-tagged N-terminal human
and mouse proteins (green, B, D) colocalized with
the DAPI-stained nuclei (C, E) in expressing cells.
A control GFP construct exhibited diffuse
epi¯uorescence throughout the cytoplasm and
nucleus as observed previously (Fig 6G, H;
Kuechle et al, 1999). Scale bars: (A) 25 mm, (B)±
(E) 10 mm.
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and that these sequences are suf®cient to account for the nuclear
accumulation of these proteins in vitro.
DISCUSSION
The pro®laggrin N-terminal peptide contains functional
nuclear localization signals Pro®laggrin undergoes proteolytic
processing during epidermal terminal differentiation to generate
two stable end-products, ®laggrin and the N-terminal peptide.
Whereas the function of ®laggrin as a keratin binding and
aggregating protein and as a likely source of hygroscopic amino
acids in the stratum corneum has been extensively studied (Dale et
al, 1978; Steinert et al, 1981; Manabe et al, 1991; Rawlings et al,
1994), the function of the released N-terminal peptide is unknown.
In this study we show that the cationic B domain of human and
mouse pro®laggrin contains functional nuclear localization se-
quences of the bipartite type, supporting a role for this peptide in
nuclear events during epidermal terminal differentiation. In human
pro®laggrin, mutation or deletion of the bNLS prevented its
nuclear translocation in transfected epithelial cells demonstrating
that it functions as a nuclear targeting signal (Fig 6). These NLSs
probably account for the observed accumulation of the processed
human pro®laggrin N-terminus in epidermal granular and transi-
tion cells (Ishida-Yamamoto et al, 1998; Presland and Dale, 2000).
Mouse epidermis was more dif®cult to study because of the rapid
transition from granular to corni®ed cells; however, the mouse N-
terminus also localized to the nuclei of transfected epithelial cells
(Figs 5, 7).
The pro®laggrin N-terminal peptide is an S100-like calcium-
binding protein (Presland et al, 1995) that can show either a
cytoplasmic or nuclear localization depending on whether or not it
is attached to ®laggrin sequences, which is presumably a function of
differentiation (see Fig 8). S100 proteins function by binding to
target proteins in a calcium-regulated manner (reviewed in Donato,
1999). Like other S100 proteins, the pro®laggrin N-terminal
peptide undergoes a conformational change upon Ca2+ binding,
suggesting that it might function like other S100 proteins by
binding target proteins within the cytoplasm or nucleus (Presland et
al, 1995). These downstream targets might include nuclear proteins
such as proteases or nucleases involved in nuclear breakdown or
cytoplasmic proteins that the pro®laggrin N-terminal peptide
transports to the nucleus. Alternatively, the N-terminal peptide
might function as a DNA-binding protein consistent with the basic
nature of the B domain, which shows some similarity to nucleic
acid binding proteins such as histones. Other examples of EF-hand
proteins that are present in both the nuclear and cytoplasmic
compartments include the p53-regulated gene S100A2 (CaN19)
(Deshpande et al, 2000), S100A6 (calcyclin) (Stradal and Gimona,
1999), and calmodulin (Deisseroth et al, 1998). S100A2, now
classi®ed as a tumor suppressor gene, is believed to function in the
cellular proof-reading response to oxidative stress, whereas nuclear
calmodulin functions to activate the transcription factor CREB via
phosphorylation. The highly speci®c expression and release of the
pro®laggrin N-terminal peptide into the nuclei of epidermal cells
coincident with terminal differentiation suggests a role for this
peptide in nuclear events related to the normal desquamation
process.
Processing of the mouse pro®laggrin N-terminus occurs in
two stages, and the products are associated with different
subcellular compartments Our results suggest that pro®laggrin
N-terminal processing occurs in two steps, generating ®rst a protein
(50 kDa) that contains a truncated ®laggrin unit and subsequently
the free N-terminus (28±30 kDa). The enzyme that carries out this
initial cleavage downstream of the truncated ®laggrin unit might
correspond to the protease that cleaves the YYY sequence of the
mouse ®laggrin linker (Resing et al, 1989; 1995a; 1995b), or a
different protease. Only the initial 50 kDa processing intermediate
was detected in cultured MEKs suggesting that the protease that
releases the free N-terminus, e.g., furin or a related PC (Pearton et
al, 2001) is not functional in cultured MEKs. The cytoplasmic
localization of N-terminal ®laggrin proteins (analogous to the
50 kDa pro®laggrin peptide detected in cultured MEKs) can be
accounted for by the strong af®nity of ®laggrin units for
cytoplasmic keratin IFs (Dale et al, 1997; Kuechle et al, 1999;
Presland et al, 2001).
Previously, we proposed that human pro®laggrin undergoes N-
terminal processing to release the free N-terminal peptide of
32 kDa (Presland et al, 1997). Similarly, in mouse epidermis only
the free N-terminal peptide was detected (Fig 4A). The absence of
N-terminal peptide containing ®laggrin sequences, i.e., the 50 kDa
species, in mouse epidermis suggests that this processing inter-
mediate is rapidly cleaved in vivo to generate the free N-terminal
peptide.
This mechanism allows ®ne control of the two disparate
functions of pro®laggrin. Removal of the N-terminal ®laggrin
peptide would leave the poly®laggrin region available for
proteolytic processing while this N-terminal peptide is retained in
the cytoplasm. Subsequent removal of the half-®laggrin (truncated)
®laggrin domain frees the N-terminal domain, which is translo-
Figure 7. Identi®cation of nuclear localization sequences in the mouse pro®laggrin N-terminus. Mouse pro®laggrin±GFP fusion constructs
were transfected into COS-7 cells and analyzed by epi¯uorescence to determine intracellular distribution of GFP signal (A±E) relative to a DAPI
counterstain to identify nuclei (not shown). Constructs were named according to the number of amino acids of mouse pro®laggrin N-terminus they
contain. MP192±GFP and MP174±GFP, containing four and two intact NLSs, respectively, are speci®cally localized to nuclei of transfected cells
whereas other MP±GFP constructs show mostly a cytoplasmic distribution (summarized in Table I). Scale bar: 10 mm.
Table I. Summary of nuclear/cytoplasmic distribution of
mouse pro®laggrin±GFP constructsa
Construct Contains Nuclear Cytoplasmic
MP192±GFPb NLS1±4 ++ +/±
MP174±GFP NLS1, 2 ++ +/±
MP161±GFP NLS1 + ++
MP145±GFP None +/± ++
MP131±GFP None +/± ++
aResults summarize the intracellular (nuclear versus cytoplasmic) distribution of
mouse pro®laggrin N-terminus constructs that contain variable numbers of nuclear
localization signals present in the mouse sequence (Fig 1). Data were derived from
several experiments, including the results presented in Fig 7.
bConstructs were named according to the number of amino acids of mouse pro-
®laggrin N-terminus they contain. MP, mouse pro®laggrin.
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cated to the nucleus where we postulate it functions in nuclear
events related to terminal differentiation.
A model for the control of pro®laggrin processing and
regulated subcellular localization of its two products Based
on the ®ndings reported here, as well as earlier studies, the
following model is proposed for pro®laggrin processing during the
granular to corni®ed cell transition (Fig 8). Pro®laggrin is
synthesized in the epidermal granular layer where it is rapidly
phosphorylated and accumulates in keratohyalin granules.
Sequestration of this phosphoprotein in keratohyalin prevents
premature association between ®laggrin and keratin, which has
deleterious effects on cell structure and viability in vitro (Dale et al,
1997; Kuechle et al, 1999; Presland et al, 2001).
As terminal differentiation occurs, the ®rst N-terminal processing
event occurs, releasing a peptide containing the N-terminal domain
and the truncated (half-®laggrin) unit. This peptide corresponds to
the abundant 50 kDa polypeptide seen in cultured MEKs grown in
low Ca2+ (Fig 4). Cleavage of the N-terminal peptide from
pro®laggrin, coupled with dephosphorylation, may loosen the
pro®laggrin aggregate and allow greater access to further proteolytic
enzymes, facilitating processing of the pro®laggrin intermediates,
i.e. the poly®laggrin region, to ®laggrin.
The ®rst N-terminal processing event is possibly the ®rst
proteolytic event in pro®laggrin processing and might occur shortly
after initiation of pro®laggrin processing in upper granular or
``transition'' cells. Subsequently, a calcium-dependent proteolytic
cleavage occurs rapidly in transition cells (Fig 8) and results in
release of the free N-terminus from the half-®laggrin sequence.
The protease that carries out this second cleavage event may be
either furin or a related PC enzyme (Pearton et al, 2001). The free
N-terminal peptide then translocates to the nucleus.
Immunohistochemical studies suggest that some N-terminal
peptide is not transported to the nucleus, but rather is incorporated
into the corni®ed envelope (Presland et al, 1997).
In contrast to the N-terminal peptide, the poly®laggrin portion is
processed to mature ®laggrin units that bind to, and aggregate, the
keratin IFs (Fig 8). These aggregated ®laments form the dense
macro®brils of corni®ed cells and protect the keratins from
proteolytic destruction (Manabe et al, 1991). In the upper corni®ed
layers, ®laggrin is ®nally processed to free amino acids including the
compound pyrrolidone carboxylic acid derived from glutamine
residues (Thulin and Walsh, 1995). These modi®ed amino acids are
thought to help maintain the osmotic balance in the outer corni®ed
layers (Rawlings et al, 1994; Presland and Dale, 2000).
In summary, we present evidence for nuclear localization of the
pro®laggrin N-terminus, an event that occurs upon its removal
from pro®laggrin during terminal differentiation. The N-terminal
processing of pro®laggrin occurs in two steps, which enables
keratinocytes to regulate the subcellular localization of its end-
products, thus allowing cells to control pro®laggrin processing and
possibly other events in terminal differentiation where these end-
products of pro®laggrin proteolysis function.
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